307 related articles for article (PubMed ID: 16981009)
1. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.
Paniagua RT; Sharpe O; Ho PP; Chan SM; Chang A; Higgins JP; Tomooka BH; Thomas FM; Song JJ; Goodman SB; Lee DM; Genovese MC; Utz PJ; Steinman L; Robinson WH
J Clin Invest; 2006 Oct; 116(10):2633-42. PubMed ID: 16981009
[TBL] [Abstract][Full Text] [Related]
2. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.
Paniagua RT; Chang A; Mariano MM; Stein EA; Wang Q; Lindstrom TM; Sharpe O; Roscow C; Ho PP; Lee DM; Robinson WH
Arthritis Res Ther; 2010; 12(1):R32. PubMed ID: 20181277
[TBL] [Abstract][Full Text] [Related]
3. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
Dewar AL; Cambareri AC; Zannettino AC; Miller BL; Doherty KV; Hughes TP; Lyons AB
Blood; 2005 Apr; 105(8):3127-32. PubMed ID: 15637141
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice.
Koyama K; Hatsushika K; Ando T; Sakuma M; Wako M; Kato R; Haro H; Sugiyama H; Hamada Y; Ogawa H; Nakao A
Mod Rheumatol; 2007; 17(4):306-10. PubMed ID: 17694264
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of c-fms by imatinib: expanding the spectrum of treatment.
Dewar AL; Zannettino AC; Hughes TP; Lyons AB
Cell Cycle; 2005 Jul; 4(7):851-3. PubMed ID: 15917650
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.
Juurikivi A; Sandler C; Lindstedt KA; Kovanen PT; Juutilainen T; Leskinen MJ; Mäki T; Eklund KK
Ann Rheum Dis; 2005 Aug; 64(8):1126-31. PubMed ID: 16014680
[TBL] [Abstract][Full Text] [Related]
8. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.
Akashi N; Matsumoto I; Tanaka Y; Inoue A; Yamamoto K; Umeda N; Tanaka Y; Hayashi T; Goto D; Ito S; Sekiguchi K; Sumida T
Mod Rheumatol; 2011 Jun; 21(3):267-75. PubMed ID: 21188449
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.
Terabe F; Kitano M; Kawai M; Kuwahara Y; Hirano T; Arimitsu J; Hagihara K; Shima Y; Narazaki M; Tanaka T; Kawase I; Sano H; Ogata A
Mod Rheumatol; 2009; 19(5):522-9. PubMed ID: 19568828
[TBL] [Abstract][Full Text] [Related]
10. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
[TBL] [Abstract][Full Text] [Related]
12. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
[TBL] [Abstract][Full Text] [Related]
13. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
14. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
De Pas T; Toffalorio F; Colombo P; Trifirò G; Pelosi G; Vigna PD; Manzotti M; Agostini M; de Braud F
J Thorac Oncol; 2008 Aug; 3(8):938-41. PubMed ID: 18670317
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate: an innovation in treatment of autoimmune diseases.
Azizi G; Mirshafiey A
Recent Pat Inflamm Allergy Drug Discov; 2013 Sep; 7(3):259-67. PubMed ID: 23947692
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib protects the murine liver from ischemia/reperfusion injury.
Ocuin LM; Zeng S; Cavnar MJ; Sorenson EC; Bamboat ZM; Greer JB; Kim TS; Popow R; DeMatteo RP
J Hepatol; 2012 Oct; 57(4):766-73. PubMed ID: 22641092
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.
Crespo O; Kang SC; Daneman R; Lindstrom TM; Ho PP; Sobel RA; Steinman L; Robinson WH
J Clin Immunol; 2011 Dec; 31(6):1010-20. PubMed ID: 21847523
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
Heinrich MC; Griffith DJ; Druker BJ; Wait CL; Ott KA; Zigler AJ
Blood; 2000 Aug; 96(3):925-32. PubMed ID: 10910906
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
